z-logo
Premium
Sclerosing odontogenic carcinoma – what we know so far
Author(s) -
O'Connor R.C.,
Khurram S.A.,
Singh T.,
Jones K.
Publication year - 2019
Publication title -
oral surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.156
H-Index - 11
eISSN - 1752-248X
pISSN - 1752-2471
DOI - 10.1111/ors.12391
Subject(s) - medicine , enucleation , curettage , neck dissection , radiation therapy , surgery , maxilla , dissection (medical) , carcinoma , radiology , pathology , dentistry
Abstract Sclerosing odontogenic carcinoma ( SOC ) was described in 2008 and is recognised as a malignant odontogenic tumour in the World Health Organisation classification of head and neck tumours. Nine cases have been reported including six in the mandible and three in the maxilla. After initial controversy over whether SOC was a variant of an odontogenic tumour or a separate entity, it is now established as a distinct entity with an infiltrative and invasive pattern but is usually a diagnosis of exclusion as other odontogenic neoplasms should be ruled out first. They are low‐grade tumours most commonly exhibiting perineural and soft tissue invasion, but distant metastases have not been reported. Treatment varies from radical resection, neck dissection and radiotherapy to enucleation or curettage with no adjuvant treatment. There has been one reported recurrence, occurring eight months after curettage, which was treated with segmental mandibular resection, but no incidences of disease‐related mortality. We report a case of SOC initially treated as an odontogenic fibroma by enucleation. Once the diagnosis of SOC was confirmed, local excision without neck dissection or radiotherapy was undertaken. The patient remains disease‐free, suggesting local excision might be sufficient treatment. Treatment standardisation cannot be possible without more reported cases.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here